LENZ Therapeutics and Lotus Pharmaceutical Forge $125 Million Deal for Presbyopia Treatment in Southeast Asia
LENZ Therapeutics has partnered with Lotus Pharmaceutical in a deal worth up to $125 million plus double-digit royalties to commercialize LNZ100, an aceclidine-based eye drop for presbyopia, in Korea and Southeast Asia.
© Copyright 2025. All Rights Reserved by MedPath